Topical, intravaginal microbicides and spermicides are greatly needed to prevent transmission of sexually transmitted diseases and/or unwanted pregnancies. The development of such compounds is a high research priority. The presumed method of action of existing, or novel, microbicides/spermicides is to provide a chemical barrier to the vaginal epithelium preventing exposure to micro-organisms. Other intravaginal products are used to treat vaginal bacteria of fungal infections. Little is known, however, about the actual or optimal initial distribution and subsequent spread of medications placed in the vagina. We describe a sensitive new technique to quantify the spread of a gel placed in the vagina using magnetic resonance imaging (MRI). Five millilitres of an over-the-counter spermicide containing Nonoxynol-9 was mixed with Gadolinium. MRI was used to quantify spread of the mixture 10 min after insertion with a standard applicator. We demonstrated contiguous spread of gel throughout the vagina. The coverage of material was thicker in the upper vagina than in the lower vagina. We also demonstrated, for the first time, that spermicidal compounds may migrate from the vaginal canal into the endocervix within 10 min of insertion. This finding suggests that topical microbicides/spermicides may act both in the vaginal canal and in the upper female genital tract.
Introduction
spermatozoa before they enter the upper female genital tract. The sites of HIV infection within the female reproductive tract As sexually transmitted infections such as chlamydia, gonorare not known. There is evidence to suggest that macrophages rhoea and HIV are among the most common causes of illness and Langerhans' cells, located throughout the vaginal epithein the world (Gerbase et al., 1998) , the development of lium, are likely targets (Spira et al., 1996; Miller, 1998 ; Sodora prophylactic intravaginal microbicides and viricides is a high et al., 1998). Thus, a topical anti-HIV preparation would research priority (Elias and Coggins, 1996; Hitchcock and optimally cover the entire vaginal epithelium to prevent transFransen, 2000). To date, only Nonoxynol-9 has been shown mission of the virus. It is possible, however, that the cells of to offer some protective benefit against transmission of some the upper genital tract such as the endocervical, endometrial of these pathogens (Cook and Rosenberg, 1998; Louv et al., or tubal mucosa may also be target sites of infection. Currently 1998; Niruthisard et al., 1992) but its effect on HIV is yet to it is unknown if a topical microbicide migrates, or is transbe demonstrated (Weir et al., 1995; Roddy et al., 1998) . New ported, into the upper genital tract. If so, does such migration microbicides, which may be used as prophylactics to prevent serve any function? the spread of sexually transmitted infections, especially HIV, Magnetic resonance imaging (MRI) has been successfully are currently under development (Elias and Coggins, 1996;  used to image the female pelvis and detect vaginal or other Hitchcock, 2000) .
Mullerian anomalies with high sensitivity (Siegelman et al., Little is known about the optimal distribution of a vaginally 1997; Barnhart et al., 2001) . This investigation was performed placed gel used for sexually transmitted diseases (STD) prophyto establish if MRI could be used to determine the intravaginal laxis and protection from unwanted pregnancy. The in-vivo distribution of an over-the-counter vaginal product in a human mechanism of action of topical spermicide/microbicide is not subject and determine if any of the gel could be detected known, but it has been presumed to act locally in the vaginal canal. A spermicide may act at, or near, the exocervix to kill outside the vaginal canal. 
Materials and methods
taken in the AP and transverse plane); (iii) at the flexure of the vagina After obtaining institutional approval to perform this experiment on as it passes through the pelvic diaphragm (AP and transverse); (iv) human subjects, a single nulliparous volunteer with normal menstrual at the mid-lower vagina, 3 cm above the introitus (AP and transverse); cycles and no gynaecological pathology was recruited. This subject and (v) just above (1 cm) the introitus (AP and transverse). underwent a MRI scan of the pelvis following the insertion of 5 ml of Gynol-II ® (Advanced Care Products, North Brunswick, NJ, USA) mixed with a previously determined concentration of 1:100 of
Results

Gadolinium-based MR contrast material [gadolinium chelate magniv-
Quantification of spread of gel in the vaginal canal
ist (gadopentate dimeglumine; Berlex Laboratories, Wayne, NJ, USA)] ( Barnhart et al., 2001) . The mixture was self-inserted using a standard After 10 min the gel spread within the vaginal canal providing clinical applicator. The subject then ambulated to the MRI table. MR a contiguous covering of the epithelium of variable thickness.
images were obtained 10 min after insertion. The MRI was performed Gel thickness and transverse spread were quantified in demarcin the mid-follicular phase of the menstrual cycle (day 8 from last ated sites in the vagina ( Figure 1A ). The majority of gel was normal menstrual period). Images were obtained using a fat-saturated, visualized in the upper vagina as demonstrated by an increase T1-weighted gradient echo using a GE 1.5T Signa scanner (GE in the thickness of the gel (AP measurements) at or above the Medical Systems, Milwaukee, WI, USA) with the assistance of a pelvic diaphragm. In the posterior vaginal fornix there was phased array surface coil centred on the pelvis as previously described 2 mm of gel noted in the AP dimension and 31 mm noted in (Barnhart et al., 2001) . 36 mm in the transverse dimension. Three centimetres above gel thickness to 1 mm. The amount of material transported to the upper tract cannot be easily quantified. Small amounts of the introitus there was 1 mm of gel in the AP and 20 mm in the transverse dimension. One centimetre above the introitus gel are likely to be taken up into the upper tract. The material is diluted as it moves from the vagina, to the endocervical there was 3 mm of gel in the AP and 29 mm in the transverse dimension.
canal, into the endometrial cavity and possibly into the Fallopian tubes.
Visualization of gel outside the vaginal canal
It is critical to describe and quantify the distribution of intravaginal products in order to optimize their formulation The majority of the gel was located in the vaginal canal.
(e.g. volume, viscosity, bioadhesive properties). The demonHowever, spread of material into the cervical canal is clearly stration of transport of topical vaginal medications into the demonstrated in Figure 1A and 1B. Additionally, some leakage upper genital tract has important clinical implications. Transof material from the introitus was noted ( Figure 1C) . port into the cervix, uterus and tubes may represent an important unrecognized contraceptive or microbicidal mechanism of Discussion action of these compounds. The vaginal mucosa is relatively inert compared with that of the endocervix or endometrium Our data demonstrate that a vaginally-placed product spreads contiguously throughout the vagina. Some of the material is (Barnhart and Shalaby, 1998) . Gonorrhoea in women usually involves the endocervix and may result in pelvic inflammatory lost as discharge from the introitus and importantly some is visualized in the upper female genital tract. These images depict disease. Primarily, gonococcal infection of the vagina is rare (Sweet and Gibbs, 1995) . Chlamydia trachomatis has been for the first time the identification of a labelled contraceptive preparation in the endocervix as soon as 10 min after vaginal implicated in endocervicitis, endometritis and pelvic inflammatory disease. It does not cause vaginitis or appear to grow administration. While this finding is based on only a single patient, it strongly suggests that vaginal products are transin vaginal squamous epithelium (Sweet and Gibbs, 1985) . The site of HIV transmission in the female genital tract has yet to ported into the upper genital tract of at least some women.
It has been assumed that, to provide contraception, a be definitively determined, but the portal of entry may be via endocervical or other upper genital tract mucosa. Thus, spread spermicidal compound should kill spermatozoa before they enter the upper genital tract (Sangi-Haghpeykar et al., 1996;  of a compound prophylactic against sexually transmitted infection to the upper tract, where infection may be more likely to Mauck et al., 1997a,b) . However, spermatozoa are located in the cervical mucus almost immediately after coitus (Sobrero take place, may be advantageous or even optimal. Conversely, since topically placed compounds may enter the upper tract, or and McLeod, 1962). Additionally, spermatozoa are transported to the oviduct and peritoneal cavity almost immediately after be absorbed systemically, their safety should be demonstrated. insemination in rabbits (Overstreet and Cooper, 1978) dead spermatozoa results in rapid transport into the upper genital tract (Drobnis and Overstreet, 1993) . There is evidence References that rapid sperm transport though the female genital tract is Barnhart, K. and Shalaby, W. (1998) The vagina: physiologic characteristics provided by uterine contractions (Kunz et al., 1996) . Imaging pp. 1-17. Barnhart, K.T., Pretorius, E.S., Stolpen, A. and Malamud, D. (2001) into the Fallopian tubes following deposition at the external Distribution of topical medication in the human vagina as imaged by MRI.
os of the cervix (Kunz et al., 1996) . This process is thought Fertil. Steril., in press. to be mediated by uterine peristalsis controlled by endocrine and possibly paracrine events (Kunz et al., 1998 and 'flattened' to cover the lateral aspects of the vagina. 
